Fenretinide has potential for GA

Article

Oral drug fenretinide has potential for the treatment of geographic atrophy (GA), but further studies are required.

Oral drug fenretinide has potential for the treatment of geographic atrophy (GA), but further studies are required, according to a paper featured in the journal Retina.

Dr Nathan Mata et al., Retina Associates of Cleveland Inc., Cleveland, Ohio, USA, conducted a two-year, placebo-controlled double-masked trial on 246 patients at 30 clinical sites in the US. Each patient received either 100 mg or 300 mg of oral fenretinide daily to slow lesion growth in GA.

The drug produced dose-dependent reversible reductions in serum RBP-retinol that were linked to trends in reduced lesion growth rates in GA. Patients who received 300 mg of fenretinide demonstrated a mean reduction 0.33 mm2 in the yearly lesion growth rate compared with subjects in the placebo group.

The therapeutic effect reduced the occurrence of choroidal neovascularization. It was not dose-dependent and was consistent with anti-angiogenic properties of fenretinide. These results, in addition to the known safety profile of the drug, warrant further study of fenretinide for GA treatment.

Please visit the journal here to read the abstract.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.